Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
115.28
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Sep 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,092
Open
115.28
Bid (Size)
115.21 (1)
Ask (Size)
115.24 (4)
Prev. Close
115.28
Today's Range
115.28 - 115.28
52wk Range
92.19 - 120.92
Shares Outstanding
N/A
Dividend Yield
3.01%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
September 11, 2024
Via
Benzinga
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
September 11, 2024
Via
Benzinga
Performance
YTD
+14.14%
+14.14%
1 Month
+3.46%
+3.46%
3 Month
+9.22%
+9.22%
6 Month
+16.44%
+16.44%
1 Year
+14.52%
+14.52%
More News
Read More
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
Via
Benzinga
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
September 05, 2024
Via
Benzinga
NYSE:NVS: good value for what you're paying.
September 03, 2024
Via
Chartmill
Uncovering Dividend Opportunities with NYSE:NVS.
August 23, 2024
Via
Chartmill
Good technical signals and a possible breakout for NOVARTIS AG-SPONSORED ADR.
August 07, 2024
Via
Chartmill
Why NYSE:NVS is a Top Pick for Dividend Investors.
August 02, 2024
Via
Chartmill
S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday
September 05, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
September 03, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
August 28, 2024
Via
Benzinga
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
August 28, 2024
From
Lindy Biosciences
Via
Business Wire
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
August 26, 2024
Via
Investor's Business Daily
Exposures
Product Safety
Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
August 26, 2024
Via
Benzinga
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
August 18, 2024
Via
The Motley Fool
Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug
August 13, 2024
Via
Benzinga
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
August 12, 2024
Via
Newsfile
Exposures
Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
August 08, 2024
Via
Investor Brand Network
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease
August 08, 2024
Via
Benzinga
Exposures
Product Safety
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
August 06, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
Via
FinancialNewsMedia
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
July 30, 2024
From
Arvinas Inc.
Via
GlobeNewswire
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
July 23, 2024
Via
Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
July 19, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.